^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CDH6 expression

i
Other names: CDH6, Cadherin 6, Cadherin 6, Type 2, K-Cadherin (Fetal Kidney), K-Cadherin, Cadherin-6, Kidney Cadherin, CAD6, KCAD
Entrez ID:
10ms
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models. (PubMed, Mol Cancer Ther)
R-DXd demonstrated potent antitumor activity against CDH6-expressing tumors in mice and an acceptable safety profile in monkeys. These findings indicate the potential of R-DXd as a new treatment option for patients with CDH6-expressing serous-type ovarian cancer and renal cell carcinoma in a clinical setting.
Preclinical • Journal
|
CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • CDH6 (Cadherin 6)
|
CDH6 expression
|
raludotatug deruxtecan (DS-6000)
1year
The GLI2/CDH6 axis enhances migration, invasion and mitochondrial fission of stomach adenocarcinoma cells. (PubMed, Biochem Biophys Res Commun)
However, the above effects were largely abrogated by CDH6 knockdown. In conclusion, the present study suggested that the novel GLI2/CDH6 axis could enhance the migration, invasion and mitochondrial fission of STAD cells.
Journal
|
GLI1 (GLI Family Zinc Finger 1) • CDH6 (Cadherin 6) • GLI2 (GLI Family Zinc Finger 2)
|
CDH6 expression • GLI2 overexpression
over1year
Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models (ESMO 2023)
DXd demonstrated cytotoxicity in all PDC models, regardless of CDH6 expression, whereas control ADC and anti-CDH6 naked antibody showed no growth inhibitory effects. Conclusions CDH6 is an attractive target for EOC and R-DXd is a promising agent for the treatment of CDH6-expressing EOC.
Clinical
|
CDH6 (Cadherin 6)
|
CDH6 expression
|
raludotatug deruxtecan (DS-6000)